/PRNewswire/ Illumina, Inc. (NASDAQ:ILMN) today announced the launch of TruSight™ Oncology (TSO) Comprehensive (EU), a single test that assesses multiple.
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
SAN DIEGO, March 15, 2022. | March 15, 2022
/PRNewswire/ Illumina, Inc. (NASDAQ:ILMN) today announced the launch of TruSight™ Oncology (TSO) Comprehensive (EU), a single test that assesses multiple.
This new in vitro diagnostic (IVD) comprehensive genomic profiling (CGP) kit covers a broad range of mutations and current and emerging biomarkers associated with the European Society for Medical Oncology guidelines, drug labels and clinical trials, maximizing the chances of finding actionable information from each patient s biopsy.